Fidelion Diagnostics reports 392,329 BioNexus Gene Lab Corp (NASDAQ: BGLC) shares
Rhea-AI Filing Summary
FIDELION DIAGNOSTICS PTE. LTD. is identified as a greater than 5% holder of BioNexus Gene Lab Corp and reports direct ownership of 392,329 shares of common stock. This Form 3 serves as an initial statement of holdings and does not report any specific purchase or sale transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
FIDELION DIAGNOSTICS PTE. LTD.
Role
Insider
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 392,329 shares (Direct)
Key Figures
Directly owned common shares: 392,329 shares
Holding entries reported: 1
Reported buy transactions: 0
+1 more
4 metrics
Directly owned common shares
392,329 shares
Common stock of BioNexus Gene Lab Corp held by FIDELION DIAGNOSTICS PTE. LTD.
Holding entries reported
1
Single holding entry in the non-derivative securities section for common stock
Reported buy transactions
0
No buy transactions indicated in the transaction summary for this Form 3
Reported sell transactions
0
No sell transactions indicated in the transaction summary for this Form 3
Key Terms
Greater than 5% holder, Common Stock, Unknown transaction code
3 terms
Greater than 5% holder regulatory
"Reporting person flagged as a "Greater than 5% holder" of BGLC common stock"
Common Stock financial
"Security title for the reported non-derivative holding is listed as "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Unknown transaction code regulatory
"Transaction code description field notes an "Unknown transaction code" for the entry"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the BioNexus Gene Lab Corp (BGLC) Form 3 report about Fidelion Diagnostics' holdings?
The Form 3 shows Fidelion Diagnostics directly owns 392,329 BioNexus Gene Lab Corp common shares. It identifies Fidelion as a greater than 5% holder, providing an initial statement of beneficial ownership rather than a new transaction in BioNexus Gene Lab Corp’s publicly traded common stock.
Is Fidelion Diagnostics a director or officer of BioNexus Gene Lab Corp (BGLC)?
Fidelion Diagnostics is reported solely as a greater than 5% holder of BioNexus Gene Lab Corp. It is not listed as a director or officer, and no officer title is provided, emphasizing its role as a significant shareholder rather than part of company management.
Does the BGLC Form 3 show any buy or sell transactions by Fidelion Diagnostics?
The Form 3 does not report any buy or sell transactions for Fidelion Diagnostics. Instead, it records an initial holding entry showing direct ownership of 392,329 common shares, so the report is about existing ownership rather than recent trading activity in BGLC stock.
What type of ownership does Fidelion Diagnostics have in BioNexus Gene Lab Corp (BGLC)?
Fidelion Diagnostics’ reported position in BioNexus Gene Lab Corp common stock is classified as direct ownership. The Form 3 indicates this through a direct ownership code, meaning the shares are held directly by the reporting entity rather than through an intermediary or indirect structure.